India's Generics Industry Faces 70% China API Dependence as $247.8 Billion Market Warning Deepens
Updated
Updated · Down To Earth Magazine · Jul 13
India's Generics Industry Faces 70% China API Dependence as $247.8 Billion Market Warning Deepens
3 articles · Updated · Down To Earth Magazine · Jul 13
Summary
Drug Patent Watch's 2026 report says India sources about 70% of its API needs from China, with dependence rising to 90% for inputs used in key antibiotics such as cephalosporin and penicillin.
That vulnerability stems from years of importing cheaper Chinese key starting materials, intermediates and APIs, a shift that hollowed out India's own manufacturing base even as it became a major exporter of low-cost generics.
6 APA, a critical input for penicillin-class antibiotics, is cited as a flashpoint: if China curbed exports, Indian production of penicillin and amoxicillin could collapse within weeks.
Rs 6,940 crore in pharma PLI support and Rs 4,763.34 crore of investment by December 2025 have made only a limited dent, leaving India far from self-sufficiency in a global API market the report values at $247.8 billion.
The report argues China's edge is widening beyond commodity inputs, with rising FDA Drug Master File submissions suggesting future generic launches in Western markets may increasingly depend on Chinese manufacturing processes.
With AI now designing novel drugs, is India’s pharma industry becoming dangerously dependent on its biggest rival, China?
As a $200B patent cliff hits pharma, can AI create new blockbuster drugs faster than generics can erase old profits?
AI can identify a new drug candidate in months, but why has no AI-discovered medicine been approved for human use yet?
Breaking the Chain: India’s 70% API Dependence on China and the Global Pharmaceutical Supply Crisis (2026)
Overview
India, known as the 'pharmacy of the world,' faces a deepening crisis due to its overwhelming reliance on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). This dependence has grown because Indian generics companies did not reassess their competitive position, allowing China to surpass them in crucial supply chain segments. As a result, India's vulnerability threatens not only its own pharmaceutical industry but also global drug supply chains, impacting medicine availability and pricing worldwide. If India's access to Chinese APIs is disrupted, many countries relying on Indian generics could experience shortages, highlighting the urgent need for stronger, more resilient supply chains.